📰 Press Release: tinyurl.com/mr25aydn 📽 Interview: youtu.be/1K6kIjQ1PZc “We are creating curated datasets, supported by wet-lab research, to fuel the creation of reliable foundational AI models." $TVGN #ArtificialIntelligence #JPM2025 Microsoft Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq)

📰 Press Release: tinyurl.com/3w9js3ep PredicTcell, Tevogen Bio’s proprietary technology, is designed for predictive, precision T cell target identification. $TVGN #affordable #accessible #celltherapy #biotech #ArtificialIntelligence Microsoft Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq)

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… “It has been exciting to see Tevogen.AI combine its carefully curated proprietary datasets with its innovative application of generative AI models to derive valuable insights that are optimized for the specific

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… This announcement marks the third foundational support pillar for Tevogen AI , the Company’s AI initiative which aims to transform precision medicine: Microsoft Research – contributing digital infrastructure, scientific

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… “Healthcare is one of the largest segments of our economy, projected to approach $5 trillion in the U.S. in 2025 and a significant contributor to our rising national debt. Tevogen.AI’s vision extends beyond

Tevogen: 300+ years of experience in drug development, commercialization, investment banking, & the emerging field of $AI in healthcare. 🌐tevogen.com/about/#Leaders… #TechInHealthcare #BiopharmaFuture #AIinHealthcare #GrowthCatalyst $TVGN #Leadership #PurposeDriven

⏳ 𝐓𝐞𝐯𝐨𝐠𝐞𝐧 𝐓𝐢𝐦𝐞 𝐂𝐚𝐩𝐬𝐮𝐥𝐞 ⏳ Mittul Mehta CIO and Head of Tevogen.AI in conversation with Brad Mehl of Future Sights and Medium about AI Innovation in Drug Discovery. 👉medium.com/future-sights/… "One of the most interesting use cases that we deal

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… $TVGN #affordable #accessible #celltherapy #AI #ArtificialIntelligence Microsoft Databricks · Tevogen.AI’s model drastically reduces target analysis and has the potential to generate billions in cost savings

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… ▪ Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapies ▪ Initiative to support Tevogen Bio’s ExacTcell™ pipeline with a goal of enhancing commercial viability and

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… “As a mission-driven innovator, Tevogen.AI believes that AI has the potential to significantly reduce the cost and time required to bring life-saving treatments to patients in need,” said Ryan Saadi, MD, MPH,

📰 𝐏𝐫𝐞𝐬𝐬 𝐑𝐞𝐥𝐞𝐚𝐬𝐞: globenewswire.com/news-release/2… 🔹Tevogen.AI to explore external market opportunities as a potential revenue source. 🔹Beta version to incorporate oncology targets, enhancing the accuracy and diversity of the PredicTcell model and potentially

American patients have waited long enough. America needed a healthcare enterprise that didn’t require billions. They said it was impossible. They were wrong. 5.5 years. ~$40M. Founders still own the majority and the mission. Meet Tevogen 🇺🇸 — a purpose-driven healthcare

🍂 As we approach Thanksgiving, we cannot think of a better time to express our immense gratitude to each of you for embracing our mission. Wishing you and those you hold dearest a Happy Thanksgiving, filled with health, love, and gratitude.🍃 $TVGN